BioNexus Gene Lab (BGLC) Revenue (2018 - 2026)

BioNexus Gene Lab has disclosed Revenue across 9 years of filings, most recently posting $22842.0 for Q1 2026.

• Revenue for Q1 2026 came in at $22842.0, down 98.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.3 million (down 42.69% YoY), and the FY2025 annual result was $7.4 million, down 21.93% from the prior year.
• Revenue came in at $22842.0 for Q1 2026 at BioNexus Gene Lab, down from $483760.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $3.0 million in Q1 2022 to a low of $22842.0 in Q1 2026.
• The 5-year median for Revenue is $2.5 million (2022), against an average of $2.2 million.
• Across the five-year window, Revenue increased 14.47% in 2025 and sank 98.93% in 2026, its largest moves.
• BioNexus Gene Lab's Revenue stood at $2.8 million in 2022, then dropped by 19.95% to $2.3 million in 2023, then rose by 11.03% to $2.5 million in 2024, then slumped by 80.83% to $483760.0 in 2025, then slumped by 95.28% to $22842.0 in 2026.
• The last three Revenue figures came in at $22842.0 (Q1 2026), $483760.0 (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.